Trial Finds Psilocybin May Work as Effectively as Common Antidepressants

A clinical trial whose results were published last week has found that psilocybin may be used to treat depression. The phase 2 study was the first randomized trial that compared the effectiveness of commonly prescribed antidepressants with therapeutic doses of psilocybin. Its findings were reported in the “New England Journal of Medicine.” The trial was conducted by scientists from the Imperial College London.

Despite the reported findings, there is still more that needs to be determined with regard to the use of psychedelics as a treatment for various mental health conditions, as researchers aren’t sure whether the substances, psilocybin included, can be effective treatments in the long term, considering that research on these substances is still in its infant stages.

The trial, which was conducted over a six-week period, had 59 participants. Prior to the study’s commencement, 40% of the participants who had been on anti-depressant medications had to taper off the drugs. During the study, 30 participants received a daily placebo pill for the entirety of the trial, in addition to two 25 mg psilocybin doses that were administered three weeks apart; the remaining 29 participants received smaller amounts of psilocybin that acted as a placebo. The latter group also consumed a dose of escitalopram, which is a generic antidepressant drug, daily.

At the end of the trial period, researchers tried to determine if the participants’ symptoms of depression had improved. To do this, they had each participant be evaluated twice by clinicians and also complete two  questionnaires.

QIDS-SR-16, a self-reported questionnaire, demonstrated that the individuals who ingested the 25 mg psilocybin doses reported greater improvement in their symptoms of depression in comparison with the individuals who ingested escitalopram.

The team of researchers, which included the head of the Center for Psychedelic Research, Robin Carhart-Harris and some of his colleagues, noted that they were not able to measure psilocybin’s long-term effects in comparison with escitalopram, as the latter takes a longer period of time to begin working. Despite the study’s limitations, however, their research findings add to a growing body of research which proposes that psychedelics could be utilized in clinical settings as a treatment for depression and may likely have lasting effects.

Johns Hopkins University director of the Center for Psychedelic and Consciousness Research Roland Griffiths stated that this discovery was significant, as it demonstrated that psilocybin, which is the active ingredient found in magic mushrooms, was as good and maybe even better than the medications currently prescribed to manage depression.

With such research findings, there is renewed hope that the tried and tested scientific teams working with companies such as Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) will soon develop psychedelic-based medicines that will provide relief to patients with mental health conditions which are currently unresponsive to the existing remedies.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050